Alzheimer’s disease, Dementia with Lewy Bodies, Huntington’s Disease, Parkinson's Disease Dementia, Stroke & Vascular dementia: Basic Research & Therapeutic Studies

Allain H, Neuman E, Malbezin M, Salzman V, Guez D, Wesnes KA, Gandon JM (1997). Bridging study of S12024 in 53 in-patients with Alzheimer's disease. Journal of the American Geriatrics Society. 45: 125-126. 

 

Almeida OP, Burton EJ, McKeith I, Gholkar A, Burn D, O’Brien JT (2003). MRI Study of Caudate Nucleus Volume in Parkinson’s disease with and without Dementia with Lewy Bodies and Alzheimer’s disease. Dementia and Geriatric Cognitive Disorders. 16: 57-63.

 

Ballard CG, Aarsland D, McKeith IG, O'Brien JT, Gray A, Cormack F, Burn D, Cassidy T, Starfeldt R, Larsen JP, Brown R, Tovee M (2002). Fluctuations in attention: PD dementia vs. DLB with Parkinsonism. Neurology. 59: 1714-1720.

 

Ballard CG, Morris CM, Rao H, O'Brien JT, Barber R, Stephens S, Rowan EN, Gibson A, Kalaria RN, Kenny RA (2004). APOE epsilon4 and cognitive decline in older stroke patients with early cognitive impairment. Neurology. 63: 1399-1402.

 

Ballard CG, O'Brien JT, Gray A, Cormack F, Ayre G, Rowan EN, Thompson P, Bucks R, McKeith IG, Walker M, Tovee M (2001). Attention and fluctuating attention in patients with dementia with Lewy bodies and Alzheimer disease. Archives of Neurology. 58: 977-982.

 

Ballard CG, Rowan EN, Stephens S, Kalaria R, Kenny RA (2003), Prospective Follow-Up Study Between 3 and 15 Months After Stroke: Improvements and Decline in Cognitive Function Among Dementia-Free Stroke Survivors >75 Years of Age. Stroke 34: 2440-2445.

 

Ballard CG, Stephens S, Kenny RA, Kalaria R, Tovee M, O'Brien JT (2003). Profile of neuropsychological deficits in older stroke survivors without dementia. Dementia and Geriatric Cognitive Disorders. 16: 52-56.

 

Ballard CG, Stephens S, McLaren A, Wesnes KA, Kenny R (2003). Mild cognitive impairment and vascular cognitive impairment in stroke patients. International Psychogeriatrics. 15: 123-126.

 

Ballard CG, Stephens S, McLaren A, Wesnes KA, Kenny RA, Burton E, O'Brien JT, Kalaria R (2002). Neuropsychological deficits in older stroke patients. Annals of the New York Academy of Sciences. 977: 179-182.

 

Ballard CG, Walker M, O'Brien JT, Rowan EN, McKeith IG (2001). The characterisation and impact of 'fluctuating' cognition in dementia with Lewy bodies and Alzheimer's disease. International Journal of Geriatric Psychiatry. 16: 494-498.

 

Barone P, Burn DJ, van Laar T, Hsu C, Poewe W, Lane RM (2008). Rivastigmine versus placebo in hyperhomocysteinemic Parkinson's disease dementia patients. Movement Disorders. 23: 1532-1540. 

 

Bronnick K, Ehrt U, Emre M, De Deyn PP, Wesnes KA, Tekin S, Aarsland D (2006). Attentional deficits affect activities of daily living in dementia associated with Parkinson's disease. Journal of Neurology Neurosurgery & Psychiatry. 77: 1136–1142.

 

Burn D, Emre M, McKeith IG, De Deyn PP, Aarsland D, Hsu C, Lane R (2006). Effects of rivastigmine in patients with and without visual hallucinations in dementia associated with Parkinson's disease. Movement disorders. 21: 1899-1907. 

 

Burton EJ, Kenny RA, O'Brien JT, Stephens S, Bradbury M, Rowan EN, Kalaria R, Firbank M, Wesnes KA, Ballard CG (2004). White matter hyperintensities are associated with impairment of memory, attention, and global cognitive performance in older stroke patients. Stroke. 35: 1270-1275.

 

Corani G, Edgar C, Marshall I D, Wesnes KA, Zaffalon M (2006). Classification of Dementia Types from Cognitive Profiles Data. In ECML 2006: Proceedings of the seventeenth European Conference on Machine Learning, Lecture Notes in Computer Science 4213, Springer, Berlin, 470–477.

 

Cummings JL (2000) Cholinesterase Inhibitors: Expanding Horizons. The Lancet 351: 2548-2549. 

 

Dujardin K, Devos D, Duhem S, Desté A, Marié R-M, Durif F, Lacomblez L, Touchon J, Pollak P, Péré J-J (2006). Utility of the Mattis dementia rating scale to assess the efficacy of rivastigmine in dementia associated with Parkinson’s disease. Journal of Neurology 253: 1154-1159.

 

Edwards K, Hershey L, Wray L, Bednarczykc E, Lichter D, Farlow M, Johnson M (2004). Efficacy and safety of Galantamine in patients with Dementia with Lewy Bodies: A 12-Week Interim Analysis. Dementia and Geriatric Cognitive Disorders. 17: 40-48.

 

Edwards K, Royall D, Hershey L, Lichter D, Hake A, Farlow M, Pasquier F, Johnson S (2007). Efficacy and safety of Galantamine in patients with Dementia with Lewy Bodies: A 24-week open label study. Dementia and Geriatric Cognitive Disorders. 23: 401-405.

 

Ellis JR, Villemagne VL, Nathan PJ, Mulligan RS, Gong SJ, Chan JG, Sachinidis J, O’Keefe GJ, Pathmaraj K, Wesnes KA, Savage G, Rowe CC (2008). Relationship between nicotinic receptors and cognitive function in early Alzheimer’s disease: A 2-[18F]fluoro-A-85380 PET study. Neurobiology of

Learning and Memory. 90: 404-412.

 

Emre M (2004) Dementia Associated with Parkinson’s disease. Lancet Neurology. 2: 229-237.

 

Emre M, Aarsland D, Albanese A, Byrne EJ, Deuschl G, De Deyn PP, Durif F, Kulisevsky J, van Laar T, Lees A, Poewe W, Robillard A, Rosa MM, Wolters E, Quarg P, Tekin S, Lane R (2004). Rivastigmine for dementia associated with Parkinson's disease. The New England Journal of Medicine. 351: 2509-2518. 

 

Emre M, Aarsland D, Brown R et al. (2007). Clinical Diagnostic Criteria for Dementia Associated with Parkinson’s Disease. Movement Disorders 22: 1689-1707.

 

Fakouhi TD, Jhee SS, Sramek JJ, Benes C, Schwartz P, Hantsburger G, Herting R, Swabb EA, Cutler NR (1995). Evaluation of cycloserine in the treatment of Alzheimer's disease. Journal of Geriatric Psychiatry and Neurology. 8: 226-230.

 

Ferris SH, Lucca U, Mohs R, Dubois B, Wesnes KA, Erzigkeit H, Geldmacher D, Bodick N (1997). Objective psychometric tests in clinical trials of dementia drugs. Position paper from the international working group on harmonization of dementia drug guidelines. Alzheimer Disease and Associated

Disorders an International Journal. 11: 34-38.

 

Frolich L, Ashwood T, Nilsson J, Eckerwall G (2011) Effects of AZD3480 on Cognition in Patients with Mild-to-Moderate Alzheimer’s Disease:A Phase IIb Dose-Finding Study. Journal of Alzheimer’s Disease 24: 363–374

 

Galvin JE, Cornblatt B, Newhouse P, Ancoli-Israel S, Wesnes KA, Williamson D, Zhu Y, Sorra K, Amatniek J (2008). Effects of Galantamine on measures of attention: Results from 2 clinical trials in Alzheimer disease patients with comparisons to Donepezil. Alzheimer Disease and Associated Disorders. 22: 30-38. 

 

Geerts H. (2006). Ispronicline (Targacept). Curr Opin Investig Drugs 1:60-69

 

Goa KL, Fitton A. (1994). Velnacrine in Alzheimer’s Disease: An Initial Appraisal of its Clinical Potential. CNS Drugs 1: 232-240. 

 

Harvey PD, Ferris SH, Cummings JL, Wesnes KA, Hsu C, Lane RM, Tekin S (2010) Evaluation of Dementia Rating Scales in Parkinson’s Disease Dementia. American Journal of Alzheimer’s Disease and Other Dementias 25:142-148

 

Herting RL (1991). Milacemide and other drugs active at glutamate NMDA receptors as potential treatment for dementia. Annals of the New York Academy of Sciences 640: 237-240.

 

Holland RL, Wesnes KA (1997). Alzheimer's disease and other dementias. Handbook of Phase I/II Clinical Drug Trials. J. O’Grady and P. H. Joubert. Boca Raton, CRC Press: 355-372.

 

Lowery DP, Wesnes KA, Ballard CG (2007). Subtle attentional deficits in the absence of dementia are associated with an increased risk of post-operative delirium. Dementia and Geriatric Cognitive Disorders. 23: 390–394.

 

Lowery DP, Wesnes KA, Brewster N, Ballard C. (2010). Subtle deficits of attention after surgery: Quantifying indicators of sub syndrome delirium. International Journal of Geriatric Psychiatry 10: 945-952.

 

Lowery DP, Wesnes KA, Brewster N, Ballard CG (2008). Quantifying the association between computerised measures of attention and confusion assessment method defined delirium: a prospective study of older orthopaedic surgical patients, free of dementia. Journal of Geriatric Psychiatry. 1-8.

 

McGuinness B, Barrett SL, Craig D, et al. (2010). Attention deficits in Alzheimer's disease and Vascular Dementia. J Neurol Neurosurg Psychiatry 81: 157-159

 

McGuinness B, Barrett SL, Craig D, et al. (2010). Executive functioning in Alzheimer’s disease and vascular dementia. International Journal of Geriatric Psychiatry 25: 562-568.

 

McKeith IG, Del Ser T, Spano P, Emre M, Wesnes KA, Anand R, Cicin-Sain A, Ferrara R, Spiegel R (2000). Efficacy of rivastigmine in dementia with Lewy bodies: a randomised, double-blind, placebo-controlled international study. Lancet. 356: 2031-2036. 

 

McKeith IG, Mintzer J, Aarsland D, Burn D, Chiu H, Cohen-Mansfield J, Dickson D, Dubois B, Duda JE, Feldman H, Gauthier S, Halliday G, Lawlor B, Lippa C, Lopez OL, Carlos Machado J, O'Brien JT, Playfer J, Reid W (2004). Dementia with Lewy bodies. Lancet Neurology. 3: 19-28.

 

McKeith IG, Wesnes KA, Perry E, Ferrara R (2004). Hallucinations predict attentional improvements with rivastigmine in dementia with Lewy Bodies. Dementia and Geriatric Cognitive Disorders. 18: 94-100. 

 

Mohr E, Knott V, Sampson M, Wesnes KA, Herting R, Mendis T (1995). Cognitive and quantified electroencephalographic correlates of cycloserine treatment in Alzheimer's disease. Clinical Neuropharmacology. 18: 28-38.

 

Mohr E, Walker D, Randolph C, Sampson M, Mendis T (1996). The utility of clinical trial batteries in the measurement of Alzheimer’s and Huntington’s dementia. International Psychogeriatrics. 8: 397-411.

 

Molloy S, Rowan EN, O'Brien JT, McKeith IG, Wesnes KA, Burn DJ (2006). The effect of levodopa on cognitive function in Parkinson's disease with and without dementia and dementia with Lewy bodies. Journal of Neurology Neurosurgery & Psychiatry. 77: 1323-1328.

 

Mosimann UP, Mather G, Wesnes KA, O'Brien JT, Burn DJ, McKeith IG (2004). Visual perception in Parkinson disease dementia and dementia with Lewy bodies. Neurology. 63: 2091-2096.

 

Nicholl CG, Lynch S, Kelly CA, White L, Simpson PM, Wesnes KA, Pitt BMN (1995). The Cognitive Drug Research computerised assessment system in the evaluation of early dementia - is speed of the essence? International Journal of Geriatric Psychiatry. 10: 199-206.

 

O'Brien JT, Wiseman R, Burton EJ, Barber B, Wesnes KA, Saxby BK, Ford GA (2002). Cognitive associations of subcortical white matter lesions in older people. Annals of New York Academy of Sciences. 977: 436-444.

 

O'Brien KK, Saxby BK, Ballard CG, Grace J, Harrington F, Ford GA, O'Brien JT, Swan AG, Fairbairn AF, Wesnes KA, del Ser T, Edwardson JA, Morris CM, McKeith IG (2003). Regulation of attention and response to therapy in dementia by butyrylcholinesterase. Pharmacogenetics. 13: 231-239. 

 

Pettersen R, Saxby BK, Wyller TB (2007). Post-stroke urinary incontinence: one-year outcome and relationships with measures of attentiveness. Journal of the American Geriatrics Society. 55: 1571-1577.

 

Press DZ (2004). Parkinson’s Disease Dementia: A First Step? New England Journal of Medicine. 351: 2547-2549. 

Rowan EN, Dickinson HO, Stephens S, Ballard CG, Kalaria R, Kenny RA (2007). Homocysteine and post-stroke cognitive decline. Age and Ageing. 36:

339-343.

 

Rowan EN, McKeith IG, Saxby BK, O'Brien JT, Burn D, Mosimann U, Newby J, Daniel S, Sanders J, Wesnes KA (2007). Effects of donepezil on central processing speed and attentional measures in Parkinson's disease with Dementia and Dementia with Lewy Bodies. Dementia and Geriatric Cognitive Disorders. 23: 161-167. 

 

Rowan EN, Morris CM, Stephens S, Ballard CG, Dickinson H, Rao H, Saxby BK, McLaren AT, Kalaria RN, Kenny RA (2005). Impact of hypertension and apolipoprotein E4 on post-stroke cognition in subjects >75 years of age. Stroke. 36: 1864-1868.

 

Schmitt FA, Aarsland D, Brønnick K et al, (2010). Evaluating Rivastigmine in Mild-to-Moderate Parkinson's Disease Dementia Using ADAS-Cog Items. American Journal of Alzheimer's Disease and Other Dementias 25: 407-413

 

Siegfried K (1991). First clinical impressions with an ACTH analogue (HOE 427) in the treatment of Alzheimer's disease. Annals of the New York Academy of Sciences 640: 260-283. 

 

Siegfried KR (1993). Pharmacodynamic and early clinical studies with velnacrine. Acta Neurol Scand 149: 26-28. 

 

Siegfried KR (1993). The pharmacodynamics of velnacrine: Results and conclusions from clinical studies in healthy subjects and patients with Alzheimer’s disease. In: Wilcock GK (Ed.) The Management of Alzheimer’s Disease. Wrightson Biomedical Publishing, pp 189-201. 

 

Simpson PM, Surmon DJ, Wesnes KA, Wilcock GK (1991). The Cognitive Drug Research computerised assessment system for demented patients: A validation study. International Journal of Geriatric Psychiatry. 6: 95-102.

 

Simpson PM, Wesnes KA and Christmas L (1989). A computerised system for the assessment of drug‑induced performance changes in young elderly or demented populations. British Journal of Clinical Pharmacology 27: 711P‑712P.

 

Stephens S, Kenny RA, Rowan EN, Allan L, Kalaria RN, Bradbury M, Ballard CG (2004). Neuropsychological characteristics of mild vascular cognitive impairment and dementia after stroke. International Journal of Geriatric Psychiatry. 19: 1053-1057.

 

Stephens S, Kenny RA, Rowan EN, Kalaria RN, Bradbury M, Pearce R, Wesnes KA, Ballard CG (2005). Association between mild vascular cognitive impairment and impaired activities of daily living in older stroke survivors without dementia. Journal of the American Geriatrics Society. 53: 103-107.

 

Tekin S, Lane R (2005). Rivastigmine in the treatment of dementia associated with Parkinson’s disease: a randomized, double-blind, placebo-controlled study. Progress in Neurotherapeutics and Neuropsychopharmacology. 1: 1-13. 

 

Templeton L, Barker A, Wesnes KA, Wilkinson D (1999). A double-blind, placebo-controlled single dose trial of intravenous flumazenil in Alzheimer's disease. Human Psychopharmacology - Clinical and Experimental. 14: 239-245.

 

Vellas B, Cunha L, Gertz HJ, De Deyn PP, Wesnes KA, Hammond G, Schwalen S (2005). Early onset effects of galantamine treatment on attention in patients with Alzheimer's disease. Current Medical Research and Opinion. 21: 1423-1429. 

 

Walker MP, Ayre GA, Ashton CH, Marsh VR, Wesnes KA, Perry EK, O'Brien JT, McKeith IG, Ballard CG (1999). A psychophysiological investigation of fluctuating consciousness in neurodegenerative dementias. Human Psychopharmacology - Clinical and Experimental. 14: 483-489.

 

Walker MP, Ayre GA, Cummings JL, Wesnes KA, McKeith IG, O'Brien JT, Ballard CG (2000). The Clinician Assessment of Fluctuation and the One Day Fluctuation Assessment Scale. Two methods to assess fluctuating confusion in dementia. The British Journal of Psychiatry. 177: 252-256.

 

Walker MP, Ayre GA, Cummings JL, Wesnes KA, McKeith IG, O'Brien JT, Ballard CG (2000). Quantifying fluctuation in dementia with Lewy bodies, Alzheimer's disease, and vascular dementia. Neurology. 54: 1616-1625.

 

Walker MP, Ayre GA, Perry EK, Wesnes KA, McKeith IG, Tovee M, Edwardson JA, Ballard CG (2000). Quantification and characterization of fluctuating cognition in dementia with Lewy bodies and Alzheimer's disease. Dementia and Geriatric Cognitive Disorders. 11: 327-335.

 

Wesnes KA (2000). Predicting, assessing, differentiating and treating the dementias: experience in MCI and various dementias using the CDR computerised cognitive assessment system. In: B. Vellas & LJ Fitten (Eds) Research and practice in Alzheimer’s disease, Volume 3. Serdi, Paris, 59-65.

 

Wesnes KA (2001). The role of attention deficits in the cognitive pathology of dementia. Alzheimer Insights. 7: 1-4.

 

Wesnes KA (2007). Rivastigmine tartrate with a focus on dementia associated with Parkinson's disease. Drugs of Today. 43: 349-359. 

 

Wesnes KA (2008). Assessing change in cognitive function in dementia: The relative utilities of the Alzheimer’s Disease Assessment Scale – cognitive subscale and the Cognitive Drug Research system. Neurodegenerative Disease. 5: 261-263.

 

Wesnes KA, Bullock R (2001). The emerging importance of attention and the speed of cognitive function in ageing and dementia research. CPD Bulletin Old Age Psychiatry. 3: 11-15.

 

Wesnes KA, Edgar C, Andreasen N, Annas P, Basun H, Lannfelt L, Zetterberg H, Blennow K, Minthon L (2010) Computerised cognition assessment during acetylcholinesterase inhibitor treatment in Alzheimer’s disease. Acta Neurologica Scandinavica 122: 270-277.

 

Wesnes KA, Harrison JE (2003). The evaluation of cognitive function in the dementias: methodological and regulatory considerations. Dialogues in Clinical Neuroscience: Dementia. 5: 77-88.

 

Wesnes KA, Hildebrand K, Mohr E (1999). Computerised cognitive assessment. Diagnosis and Management of Dementia: A Manual for Memory Disorders Teams. G. W. Wilcock, R. S. Bucks and K. Rocked. Oxford, Oxford University Press: 124-136.

 

Wesnes KA, McKeith IG, Edgar C, Emre M, Lane R (2005). Benefits of rivastigmine on attention in dementia associated with Parkinson disease. Neurology. 65: 1654-1656. 

 

Wesnes KA, McKeith IG, Ferrara R, Emre M, Del Ser T, Spano PF, Cicin-Sain A, Anand R, Spiegel R (2002). Effects of rivastigmine on cognitive function in dementia with Lewy bodies: a randomised placebo-controlled international study using the Cognitive Drug Research computerised assessment system. Dementia  and Geriatric Cognitive Disorders. 13: 183-192. 

 

Wesnes KA, Pincock C (2002). Practice effects on cognitive tasks: a major problem? Lancet Neurology. 1: 473.

Williams G, Barker RA (2007). Visual hallucinations predict increased benefits from rivastigmine in Parkinson’s disease dementia. Nature Clinical Practice Neurology. 3: 250-251.

 

Zaffalon M, Wesnes KA, Petrini O (2001). Credal classification for dementia screening. In Quaglini, S., Barahona P., Andreassen, S. (Eds), AIME '01: Proceedings of the Eighth European Conference on Artificial Intelligence in Medicine, Lecture Notes in Computer Science 2101, Springer, 67–76.

 

Zaffalon M, Wesnes KA, Petrini O (2003). Reliable diagnoses of dementia by the naive credal classifier inferred from incomplete cognitive data. Artificial Intelligence in Medicine 29: 61-79.

 

Wesnes KA, Edgar CE. (2014). The role of human cognitive neuroscience in drug discovery for the dementias. Current Opinion in Pharmacology 14: 62-73.

 

Wesnes KA, Annas P, Basun H, Edgar CE, Blennow K. (2014). Object Pattern Separation data in Alzheimer’s patients consistent with disrupted hippocampal dentate gyrus activity suggesting compromised neurogenesis is related to APOE status and CSF Aß42. Alzheimer’s Research & Therapy 6:20.

 

Wesnes KA (2014). Moving beyond the pros and cons of automating cognitive testing in pathological aging and dementia: The case for equal opportunity. Alzheimer’s Research & Therapy 6: 58  DOI: 10.1186/s13195-014-0058-1

Get in touch...

 

 

 

  • Twitter B&W